

Make a difference in ovarian cancer!



Help us develop
a blood test to
detect ovarian
cancer early!

Your Participation Matters

The MiDe (microRNA Detection) Study is working to develop a blood test to detect ovarian cancer early using microRNAs. **Early ovarian cancer is often curable.**

Eligibility

You may be eligible to participate if you:

- Are an adult over the age of 18 with at least one ovary intact and no personal history of ovarian cancer
- Have a genetic variant(s) linked to ovarian cancer on genetic testing, such as *BRCA1*, *BRCA2*, *BRIP1*, *RAD51C*, *RAD51D*, *PMS2*, *PALB2*, *MLH1*, *MSH2*, *MSH6*, or *EPCAM*
- Have a blood relative who carries a genetic variant found on genetic testing
- Have a family history of cancer, such as breast, ovarian, or gastrointestinal (GI) cancer(s)

Goals

The MiDe Study aims to:

- Better understand ovarian cancer risk for people at high risk (including people with a genetic risk or family cancer history)
- Examine the value of measuring microRNA in blood from individuals with high risk but without symptoms to detect ovarian cancer early

Ultimately, we hope to improve early detection, prevention, and treatment of ovarian cancer in women at high risk

Contact us

Phone

617-582-8833

Email

midestudy@DFCI.HARVARD.edu

Website

MiDEstudy.org